Global Human Insulin Market: Overview
Globally the demand for human insulin has
grown majorly because of increasing incidence of diabetes and obesity
that are caused by changing lifestyle and over consumption of sugar in
different variety of food and beverages. These major factors have grown
the need for human insulin and has boosted the global human insulin
market. Additionally, growing investments in research and development
activities by various organization that have eased out the way insulin
is injected have also benefitted this market. Introduction of the safety
pen needles and pen devices for effective delivery of insulin are
driving the global market for human insulin. Moreover, growing awareness
about diabetes has driven the demand in the human insulin market. Over
the course of six years from 2018 to 2026, the global human insulin
market is expected to grow at a healthy CAGR
The global human insulin market can be
segmented on the basis of type, diseases, brand, and geography. Based on
the type, the human insulin market is segmented into traditional human
insulin and modern human insulin. Out of these two, modern human insulin
is expected to experience high demand as compared to traditional human
insulin. During the forecast period, this segment is projected to across
billions and can rise at healthy CAGR.
This report provides a catholic
evaluation of the global human insulin market based on market
competition, segmentation, and dynamics. It sheds light on how the
global regenerative therapies market could shape in the near future.
Global Human Insulin Market: Trends and Opportunities
With the growing need for human insulin
this market consist various opportunities such as application of
regulations against needle anxiety, needle stick injuries, and rising
awareness related to the danger of blood borne pathogen transmission.
Additionally, increasing demand for biosimilar drugs because they are
cost effective that are considered as the growth drivers for the global
human insulin market. . However, limited access to human insulin in
emerging economies and uneven pricing may affect the market growth.
Nevertheless, with growing effort for in healthcare sector by government
and various organization may help in overcoming these limitations.
Global Human Insulin Market: Regional Analysis
Based on geography, North America is
projected to dominate the global human insulin market during the
forecast period. Owing to increasing incidence of diabetes and growing
geriatric population are considered as the major factors for the rise of
the human insulin market in this region. In terms of revenue, several
countries in Europe such as France, Germany, and Italy are projected to
show a significant contribution that may help to grow the human insulin
market during the forecast period. Meanwhile, Asia Pacific is also
anticipated to be one of the favorable markets for the growth of human
insulin. Increasing research and development initiatives by various
organization and growing government initiatives have made the region
lucrative for the growth of the human insulin market.
Global Human Insulin Market: Companies Mentioned
The global human insulin market marks the
presence of leading players such as Novo Nordisk A/S, Eli Lilly and
Company, Tonghua Dongbao Pharmaceutical Co., Adocia, Merck & Co.,
Inc., Sanofi, Biocon, Ltd., and Wockhardt.
The report offers a comprehensive
evaluation of the market. It does so via in-depth qualitative insights,
historical data, and verifiable projections about market size. The
projections featured in the report have been derived using proven
research methodologies and assumptions. By doing so, the research report
serves as a repository of analysis and information for every facet of
the market, including but not limited to: Regional markets, technology,
types, and applications.
No comments:
Post a Comment